# Clinical Relationship Between Serum ApoB, HER2, and Myocardial Ischemia Risk in Breast Cancer Patients

## TL;DR

This study identifies ApoB and HER2 as potential predictors of myocardial ischemia in breast cancer patients, offering a new approach for early cardiovascular risk assessment.

## Contribution

The study introduces a clinical prediction model using ApoB and HER2 to assess myocardial ischemia risk in breast cancer patients.

## Key findings

- ApoB, age, and HER2 were significant factors for myocardial ischemia in breast cancer patients.
- ApoB and HER2 were more predictive in breast cancer than in benign tumor patients.
- The prediction model achieved an AUC of 0.583 with clinical net benefit in a specific threshold range.

## Abstract

The risk factors and clinical prediction of cardiovascular comorbidities in patients with breast cancer have not been fully clarified.

This retrospective case–control study was designed to investigate the factors affecting myocardial ischemia occurrence in breast cancer patients.

A total of 194 cases (144 breast cancer and 50 benign breast tumor patients) were included. Univariate and multivariable Cox regression found that ApoB, age, and HER2 were significant factors responsible for the myocardial ischemia occurrence in breast cancer patients. By comparing the significance of ApoB in breast cancer patients versus benign breast tumor patients, it was observed that ApoB and HER2 were crucial predictors of myocardial ischemia in breast cancer patients compared to those with benign breast tumors. These factors were utilized to construct the clinical prediction model, achieving a combined area under the curve (AUC) of 0.583. The decision curve analysis (DCA) indicated that the model‐predicted population, within a threshold ranging from 0.35 to 0.70, would experience a therapeutically clinical net benefit. Kaplan–Meier plot indicated that ApoBhigh and HER2+ categories were high‐risk populations for myocardial ischemia in breast cancer patients, although there was no significant difference between ApoBlow and ApoBhigh subgroups for the 3‐year disease‐free survival.

We demonstrated that ApoB and HER2 were potential factors in predicting the myocardial ischemia occurrence in breast cancer patients. This study will help provide clinical evidence for the early prediction of cardiovascular comorbidities in breast cancer patients.